Compare Merck & Co., Inc. (MRK) vs Invesco S&P 500 High Div Low Volatility ETF (SPHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Invesco S&P 500 High Div Low Volatility ETF — how do they compare? Merck & Co., Inc. trades at $148.11 (market cap $366.28B), while Invesco S&P 500 High Div Low Volatility ETF trades at $51.89. The key difference: Merck & Co., Inc. pays a 2.29% dividend while Invesco S&P 500 High Div Low Volatility ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, Invesco S&P 500 High Div Low Volatility ETF nearer its low. Which is the better fit depends on your goals.
| MRK | SPHD | |
|---|---|---|
Market Cap | $366.28B | — |
Sector | Health | — |
52-Week High | $156.43 | $53.55 |
52-Week Low | $77.60 | $46.96 |
Enterprise Value | $413.04B | — |
Dividend Yield | 2.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $156.71. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending, and maintains a robust gross profit margin of 72.97%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include high valuation multiples like a P/E of 118.77 and regulatory pressures. Investors should weigh the company's solid cash flow and analyst support against potential market volatility and integration challenges from recent M&A activity.
SPHD trades at $51.96, down 0.65% today, with mixed technical signals showing a bullish overall trend but bearish moving averages. The ETF focuses on high dividend yield and low volatility, offering monthly income payments of $0.21. Recent news highlights SPHD's 4.4% yield appeal amid market volatility, though some analysts question its total return potential compared to peers like SCHD.
The outlook remains balanced between income generation and growth limitations. SPHD provides stable monthly dividends attractive for conservative investors, but faces competition from higher-quality dividend ETFs. Key risks include exposure to yield traps and weaker drawdown recovery, requiring careful consideration of total return objectives versus income needs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Invesco S&P 500 High Div Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the “index Provider”) compiles, maintains and calculates the underlying index, which is designed to measure the performance of 50 least volatile high yielding constituents of the S&P 500 ® Index in the past year.
Read more on SPHD →
